https://beonemedaffairs.com/us/publication/a-meta-analysis-investigating-response-rates-with-continuous-bruton-tyrosine-kinase-inhibitor-monotherapies-in-the-treatment-of-b-cell-lymphomas/ 2026-05-06T11:24:43+00:00 https://beonemedaffairs.com/us/publication/saffron-301-a-randomised-phase-iii-study-of-sitravatinib-in-combination-with-tislelizumab-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer/ 2026-05-06T13:05:36+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-extensive-stage-sclc-a-long-term-survival-and-programmed-death-ligand-1-subgroup-analysis-from-the-randomized-phase-3-ra/ 2026-05-06T13:09:06+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-adults-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-a-japanese-subgroup-analysis-of-rationale-306-with/ 2026-05-06T13:10:55+00:00 https://beonemedaffairs.com/us/publication/pet-ct-guided-neoadjuvant-tislelizumab-plus-chemotherapy-chemoradiotherapy-for-resectable-esophageal-squamous-cell-carcinoma-rationale-213-final-analysis/ 2026-05-06T13:22:31+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and-etoposide-as-firstline-treatment-for-extensive-stage-small-cell-lung-cancer-patient-reported-outcomes-in-the-rationale-312-tr/ 2026-05-06T13:23:46+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-for-advanced-or-metastatic-squamous-non-small-cell-lung-cancer-4-year-long-term-follow-up-from-rationale-307/ 2026-05-06T13:25:21+00:00 https://beonemedaffairs.com/us/publication/patient-medication-preferences-in-follicular-lymphoma-in-the-united-states-a-discrete-choice-experiment/ 2026-05-06T13:26:20+00:00 https://beonemedaffairs.com/us/publication/efficacy-and-safety-of-tislelizumab-as-neoadjuvant-treatment-in-patients-with-stage-ii-iii-microsatellite-instability-high-mismatch-repair-deficient-colorectal-cancer-a-single-arm-multicente/ 2026-05-06T13:27:31+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-versus-ibrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-health-related-quality-of-life-in-a-subgroup-of-chinese-patients-in-the/ 2026-05-06T13:28:31+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-for-recurrent-or-metastatic-nasopharyngeal-cancer-three-year-follow-up-of-the-phase-3-rationale-309-randomized-clinical-trial/ 2026-05-06T13:29:35+00:00 https://beonemedaffairs.com/us/publication/real-world-treatment-utilization-patterns-discontinuation-and-healthcare-resource-utilization-of-first-line-bruton-tyrosine-kinase-inhibitors-among-elderly-patients-%e2%89%a565-years-in-chron/ 2026-05-06T13:31:28+00:00 https://beonemedaffairs.com/us/publication/real-world-treatment-switching-and-sequencing-to-next-line-of-therapy-of-zanubrutinib-acalabrutinib-and-ibrutinib-in-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/ 2026-05-06T13:32:32+00:00 https://beonemedaffairs.com/us/publication/subcutaneously-administered-tislelizumab-in-locally-advanced-or-metastatic-non-small-cell-lung-cancer-pharmacokinetics-and-safety-results-from-the-bgb-a317-103-phase-i-study/ 2026-05-06T13:35:13+00:00 https://beonemedaffairs.com/us/publication/incidence-prevalence-survival-and-mortality-of-chronic-lymphocytic-leukaemia-small-lymphocytic-lymphoma-and-waldenstrom-macroglobulinaemia-in-australia/ 2026-05-06T13:36:17+00:00 https://beonemedaffairs.com/us/publication/number-needed-to-treat-to-avoid-progression-and-death-and-cost-analysis-zanubrutinib-versus-acalabrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia/ 2026-05-06T13:37:46+00:00 https://beonemedaffairs.com/us/publication/efficacy-and-safety-of-anti-pd-l1-treatments-a-systematic-review-and-meta-analysis-of-asian-vs-non-asian-patients-with-esophageal-squamous-cell-carcinoma/ 2026-05-06T13:44:29+00:00 https://beonemedaffairs.com/us/publication/have-fixed-duration-fd-regimens-delivered-on-their-promise-in-chronic-lymphocytic-leukemia-and-what-is-the-future-of-fd-regimens-a-narrative-review/ 2026-05-06T13:45:48+00:00 https://beonemedaffairs.com/us/publication/an-indirect-comparison-of-zanubrutinib-vs-acalabrutinib-plus-venetoclax-in-patients-with-treatment-naive-cll/ 2026-05-06T13:46:54+00:00 https://beonemedaffairs.com/us/publication/prolonged-progression-free-survival-with-zanubrutinib-in-relapsed-refractory-cll-an-indirect-treatment-comparison-versus-other-btk-inhibitors-using-multilevel-network-meta-regression/ 2026-05-06T13:48:08+00:00 https://beonemedaffairs.com/us/publication/prospective-patient-preference-study-for-bruton-tyrosine-kinase-inhibitor-btki-treatment-attributes-and-factors-affecting-patient-shared-decision-making-in-chronic-lymphocytic-leukemia-cll-and-sma/ 2026-05-06T13:49:08+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-efficacy-and-safety-compared-to-other-anti-pd-1s-a-network-meta-analysis-of-first-line-therapies-for-unresectable-locally-advanced-or-metastatic-esophageal-squamous-cell-carcino/ 2026-05-06T13:53:26+00:00 https://beonemedaffairs.com/us/publication/unlocking-the-potential-of-immunotherapy-for-patients-with-resectable-non-small-cell-lung-cancer/ 2026-05-06T13:54:41+00:00 https://beonemedaffairs.com/us/publication/a-systematic-literature-review-and-meta-analysis-on-the-efficacy-and-safety-of-pd-l1-inhibitors-for-the-first-and-second-line-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer/ 2026-05-06T13:56:48+00:00 https://beonemedaffairs.com/us/publication/real-world-comparative-effectiveness-of-bruton-tyrosine-kinase-inhibitors-in-relapsed-refractory-mantle-cell-lymphoma/ 2026-05-06T13:57:55+00:00 https://beonemedaffairs.com/us/publication/peri-operative-tislelizumab-plus-neoadjuvant-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-final-analysis-of-the-randomized-rationale-315-trial/ 2026-05-06T13:58:54+00:00 https://beonemedaffairs.com/us/publication/comparative-efficacy-and-safety-of-tislelizumab-in-second-line-esophageal-squamous-cell-carcinoma-systematic-literature-review-and-simulated-treatment-comparisons/ 2026-05-06T14:00:02+00:00 https://beonemedaffairs.com/us/publication/immunogenicity-of-tislelizumab-clinical-summary-of-ada-incidence-and-feasibility-of-assessing-the-suitability-of-validation-cut-points-using-statistical-methods/ 2026-05-06T14:02:31+00:00 https://beonemedaffairs.com/us/publication/zanidatamab-in-her2-positive-metastatic-biliary-tract-cancer-final-results-from-herizon-btc-01/ 2026-05-06T14:03:28+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-chemotherapy-in-gastric-cancer-long-term-rationale-305-randomized-trial-follow-up/ 2026-05-06T14:04:16+00:00 https://beonemedaffairs.com/us/publication/matching-adjusted-indirect-comparisons-of-efficacy-and-safety-for-zanubrutinib-versus-the-combination-of-fixed-duration-venetoclax-and-ibrutinib-in-patients-with-treatment-naive-chronic-lymphocytic-le/ 2026-05-06T14:05:04+00:00 https://beonemedaffairs.com/us/publication/zanidatamab-in-combination-with-docetaxel-in-first-line-her2-positive-breast-cancer-results-from-an-open-label-multicenter-phase-ib-ii-study/ 2026-05-06T14:05:56+00:00 https://beonemedaffairs.com/us/publication/comparative-efficacy-and-safety-of-tislelizumab-and-other-programmed-cell-death-protein-1-inhibitors-in-first-line-treatment-of-advanced-gastroesophageal-cancers-a-systematic-review-and-netwo/ 2026-05-06T14:07:00+00:00 https://beonemedaffairs.com/us/publication/advantig-204-a-phase-2-randomized-open-label-study-of-ociperlimab-plus-tislelizumab-and-concurrent-chemoradiotherapy-versus-tislelizumab-and-concurrent-chemotherapy-versus-concurrent-chemoradiother/ 2026-05-06T14:08:03+00:00 https://beonemedaffairs.com/us/publication/real-world-treatment-patterns-and-outcomes-of-zanubrutinib-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-cll-sll/ 2026-05-06T14:08:52+00:00 https://beonemedaffairs.com/us/publication/a-phase-i-study-of-the-ox40-agonist-bgb-a445-with-or-without-tislelizumab-an-anti-pd-1-monoclonal-antibody-in-patients-with-advanced-solid-tumors-dose-escalation-results/ 2026-05-06T14:09:49+00:00 https://beonemedaffairs.com/us/publication/epidemiology-real-world-treatment-and-economic-burden-of-waldenstrom-macroglobulinemia-a-comprehensive-analysis-based-on-anonymized-claims-data-between-2010-and-2022/ 2026-05-06T14:10:37+00:00 https://beonemedaffairs.com/us/publication/phase-ib-ii-study-of-pamiparib-plus-radiation-therapy-and-or-temozolomide-in-adult-patients-with-treatment-naive-or-recurrent-refractory-glioblastoma/ 2026-05-06T14:11:41+00:00 https://beonemedaffairs.com/us/publication/outcomes-following-transition-from-ibrutinib-to-zanubrutinib-in-patients-with-waldenstrom-macroglobulinemia-from-aspen/ 2026-05-06T14:12:26+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-in-advanced-non-squamous-non-small-cell-lung-cancer-pd-l1-%e2%89%a5-50-subgroup-analysis-from-the-rationale-304-trial/ 2026-05-06T14:13:16+00:00 https://beonemedaffairs.com/us/publication/indirect-comparisons-of-the-efficacy-and-safety-of-zanubrutinib-versus-venetoclax-plus-obinutuzumab-in-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/ 2026-05-06T14:14:10+00:00 https://beonemedaffairs.com/us/publication/real-world-treatment-patterns-of-bruton-tyrosine-kinase-inhibitors-in-mantle-cell-lymphoma-in-a-community-oncology-setting/ 2026-05-06T14:15:23+00:00 https://beonemedaffairs.com/us/publication/relative-bioavailability-food-effect-and-bioequivalence-studies-to-assess-a-new-zanubrutinib-160-mg-tablet-results-from-2-phase-1-studies-in-healthy-volunteers/ 2026-05-06T14:16:14+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-versus-acalabrutinib-indirect-treatment-comparison-in-relapsed-or-refractory-mantle-cell-lymphoma/ 2026-05-06T14:17:09+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-for-the-treatment-of-patients-with-del17p-and-or-tp53-cll-sll-analysis-across-clinical-studies/ 2026-05-06T14:17:52+00:00 https://beonemedaffairs.com/us/publication/hypertension-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-in-alpine-a-secondary-analysis/ 2026-05-06T14:18:37+00:00 https://beonemedaffairs.com/us/publication/long-term-safety-analysis-of-pooled-data-for-tislelizumab-as-monotherapy-or-in-combination-with-chemotherapy-in-patients-with-advanced-cancers/ 2026-05-06T14:19:21+00:00 https://beonemedaffairs.com/us/publication/integrated-strategy-for-biotransformation-of-antibody-drug-conjugates-and-multidimensional-interpretation-via-high-resolution-mass-spectrometry/ 2026-05-06T14:36:10+00:00 https://beonemedaffairs.com/us/publication/hpk1-kinase-inhibitor-a-sufficient-approach-to-target-hpk1-to-modulate-t-cell-activation-in-cancer-immunotherapy-compared-with-degraders/ 2026-05-06T14:37:16+00:00 https://beonemedaffairs.com/us/publication/simultaneous-analysis-of-the-drug-to-antibody-ratio-free-drug-related-impurities-and-purity-of-antibody%e2%88%92drug-conjugates-based-on-size-exclusion-chromatography/ 2026-05-06T14:38:14+00:00 https://beonemedaffairs.com/us/publication/ligand-induced-ubiquitination-unleashes-lag3-immune-checkpoint-function-by-hindering-membrane-sequestration-of-signaling-motifs/ 2026-05-06T14:38:57+00:00 https://beonemedaffairs.com/us/publication/efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-r-r-cll-a-matching-adjusted-indirect-comparison-maic/ 2026-05-06T14:39:49+00:00 https://beonemedaffairs.com/us/publication/toxicity-progression-free-survival-and-quality-of-life-of-patients-treated-with-zanubrutinib-versus-ibrutinib-a-q-twist-analysis-from-the-alpine-study-in-relapsed-or-refractory-chronic-lymphocytic/ 2026-05-06T14:40:41+00:00 https://beonemedaffairs.com/us/publication/cancer-immunotherapy-clinical-trials-to-support-urgently-needed-access-in-low-and-middle-income-countries-a-report-from-the-sitc-global-access-and-impact-committee/ 2026-05-06T14:41:26+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-of-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-patient-reported-outcomes-in-the-rationale-305/ 2026-05-06T14:42:19+00:00 https://beonemedaffairs.com/us/publication/advantig-202-phase-2-open-label-two-cohort-multicenter-study-of-ociperlimab-plus-tislelizumab-and-tislelizumab-alone-in-patients-with-previously-treated-recurrent-or-metastatic-cervical-cancer/ 2026-05-06T14:43:05+00:00 https://beonemedaffairs.com/us/publication/psychometric-validation-of-the-eortc-qlq-oes18-in-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma/ 2026-05-06T14:44:01+00:00 https://beonemedaffairs.com/us/publication/concordance-between-the-pd-l1-tumor-area-positivity-score-and-combined-positive-score-for-gastric-or-esophageal-cancers-treated-with-tislelizumab/ 2026-05-06T14:44:52+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-and-venetoclax-for-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-with-and-without-del17p-tp53-mutation-sequoia-arm-d-results/ 2026-05-06T14:45:43+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-is-well-tolerated-and-effective-in-cll-sll-patients-intolerant-of-ibrutinib-acalabrutinib-updated-results/ 2026-05-06T14:46:27+00:00 https://beonemedaffairs.com/us/publication/comparative-efficacy-of-bruton-tyrosine-kinase-inhibitors-in-high-risk-relapsed-refractory-cll-a-network-meta-analysis/ 2026-05-06T14:47:21+00:00 https://beonemedaffairs.com/us/publication/clinical-pharmacology-overview-of-tislelizumab-in-patients-with-advanced-tumors-with-a-focus-on-racial-impact/ 2026-05-06T14:48:15+00:00 https://beonemedaffairs.com/us/publication/alternative-dosing-regimens-of-tislelizumab-using-a-pharmacometrics-model-based-approach/ 2026-05-06T14:49:33+00:00 https://beonemedaffairs.com/us/publication/a-systematic-literature-review-of-the-economic-and-healthcare-resource-utilization-burden-of-relapsed-refractory-follicular-lymphoma/ 2026-05-06T14:50:20+00:00 https://beonemedaffairs.com/us/publication/comparative-effectiveness-and-safety-of-tislelizumab-versus-other-anti-pd-l1-agents-in-first-and-subsequent-lines-in-locally-advanced-or-metastatic-non-small-cell-lung-cancer-syste/ 2026-05-06T14:51:00+00:00 https://beonemedaffairs.com/us/publication/number-needed-to-treat-and-associated-cost-analysis-of-zanubrutinib-vs-ibrutinib-in-chronic-lymphocytic-leukemia/ 2026-05-06T14:51:45+00:00 https://beonemedaffairs.com/us/publication/notch1-mutation-and-survival-analysis-of-tislelizumab-in-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-a-biomarker-analysis-from-the-randomized-phase-iii-rationale-302-trial/ 2026-05-06T14:52:27+00:00 https://beonemedaffairs.com/us/publication/current-and-future-therapies-for-follicular-lymphoma/ 2026-05-06T14:53:17+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-japanese-treatment-naive-and-relapsed-refractory-patients-with-waldenstrom-macroglobulinemia-and-cll-sll/ 2026-05-06T14:55:52+00:00 https://beonemedaffairs.com/us/publication/quantitative-systems-pharmacology-model-to-predict-target-occupancy-by-bruton-tyrosine-kinase-inhibitors-in-patients-with-b-cell-malignancies/ 2026-05-06T14:56:40+00:00 https://beonemedaffairs.com/us/publication/peripheral-neuropathy-in-the-phase-3-aspen-study-of-bruton-tyrosine-kinase-inhibitors-for-waldenstrom-macroglobulinemia/ 2026-05-06T14:57:25+00:00 https://beonemedaffairs.com/us/publication/acquired-mutations-in-patients-with-relapsed-refractory-cll-who-progressed-in-the-alpine-study/ 2026-05-06T14:58:04+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-for-advanced-gastric-cancer-with-programmed-death-ligand-1-expression-%e2%89%a5-1-a-retrospective-analysis-of-rationale-305/ 2026-05-06T14:58:44+00:00 https://beonemedaffairs.com/us/publication/first-line-tislelizumab-plus-chemotherapy-for-esophageal-squamous-cell-carcinoma-with-1-programmed-death-ligand-1-expression-%e2%89%a5-1-a-retrospective-analysis-of-rationale-306/ 2026-05-06T14:59:36+00:00 https://beonemedaffairs.com/us/publication/the-epidemiological-trends-and-predictions-of-esophageal-squamous-cell-carcinoma-and-gastroesophageal-junction-carcinoma-an-australian-population-based-study/ 2026-05-06T15:00:18+00:00 https://beonemedaffairs.com/us/publication/a-randomized-placebo-controlled-trial-of-the-btk-inhibitor-zanubrutinib-in-hospitalized-patients-with-covid-19-respiratory-distress-immune-biomarker-and-clinical-findings/ 2026-05-06T15:01:03+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-versus-bendamustine-and-rituximab-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-median-5-year-follow-up-of-sequoia/ 2026-05-06T15:01:47+00:00 https://beonemedaffairs.com/us/publication/perioperative-tislelizumab-plus-neoadjuvant-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-rationale-315-an-interim-analysis-of-a-randomised-clinical-trial/ 2026-05-06T15:03:58+00:00 https://beonemedaffairs.com/us/publication/matching-adjusted-indirect-comparisons-of-zanubrutinib-magnolia-bgb-3111-au-003-versus-ibrutinib-pcyc-1121-and-rituximab-chronos-3-in-relapsed-refractory-marginal-zone-lymphoma/ 2026-05-06T15:04:40+00:00 https://beonemedaffairs.com/us/publication/saffron-104-a-phase-ib-ii-study-of-sitravatinib-alone-or-with-tislelizumab-in-advanced-hepatocellular-carcinoma-and-gastric-cancer-gastroesophageal-junction-cancer/ 2026-05-06T15:05:21+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-chemotherapy-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-squamous-non-small-cell-lung-cancer-final-analysis-of-the-randomized-phase-iii-rationale-307-trial/ 2026-05-06T15:06:03+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-chemotherapy-as-first-line-treatment-of-locally-advanced-or-metastatic-nonsquamous-non-small-cell-lung-cancer-final-analysis-of-rationale-304-a-randomized-phase-iii-trial/ 2026-05-06T15:06:45+00:00 https://beonemedaffairs.com/us/publication/sustained-benefit-of-zanubrutinib-vs-ibrutinib-in-patients-with-r-r-cll-sll-final-comparative-analysis-of-alpine/ 2026-05-06T15:08:19+00:00 https://beonemedaffairs.com/us/publication/clinician-perspective-on-once-daily-zanubrutinib-dosing-for-b-cell-malignancies-at-a-single-center/ 2026-05-06T15:09:51+00:00 https://beonemedaffairs.com/us/publication/delphi-consensus-recommendations-on-treatment-for-advanced-stage-marginal-zone-lymphoma-in-south-korea/ 2026-05-06T15:11:17+00:00 https://beonemedaffairs.com/us/publication/health-related-quality-of-life-in-patients-with-waldenstrom-macroglobulinemia-results-from-the-aspen-trial/ 2026-05-06T15:11:55+00:00 https://beonemedaffairs.com/us/publication/efficacy-and-safety-of-tislelizumab-plus-lenvatinib-as-first-line-treatment-in-patients-with-unresectable-hepatocellular-carcinoma-a-multicenter-single-arm-phase-2-trial/ 2026-05-06T15:12:46+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-in-previously-treated-locally-advanced-unresectable-metastatic-microsatellite-instability-high-mismatch-repair-deficient-solid-tumors/ 2026-05-06T15:14:38+00:00 https://beonemedaffairs.com/us/publication/improved-efficacy-and-safety-of-zanubrutinib-versus-ibrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-in-china-a-subgroup-of-alpine/ 2026-05-06T15:15:22+00:00 https://beonemedaffairs.com/us/publication/real-world-treatment-patterns-and-outcomes-for-patients-with-cll-using-the-australian-pharmaceutical-benefits-scheme-pbs-dataset/ 2026-05-06T15:16:04+00:00 https://beonemedaffairs.com/us/publication/phase-1b-study-to-assess-the-safety-tolerability-and-clinical-activity-of-pamiparib-in-combination-with-temozolomide-in-patients-with-locally-advanced-or-metastatic-solid-tumors/ 2026-05-06T15:16:56+00:00 https://beonemedaffairs.com/us/publication/clinical-dose-rationale-of-tislelizumab-in-patients-with-solid-or-hematological-advanced-tumors/ 2026-05-06T15:17:57+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-is-effective-in-non-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma-with-mutated-cd79b-high-tcl1a-expression-or-over-expressed-myc-bcl-2/ 2026-05-06T15:19:01+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-or-gastro-oesophageal-junction-adenocarcinoma-rationale-305-randomised-double-blind-phas/ 2026-05-06T15:19:45+00:00 https://beonemedaffairs.com/us/publication/effects-of-tislelizumab-on-health-related-quality-of-life-in-patients-with-recurrent-or-metastatic-nasopharyngeal-cancer/ 2026-05-06T15:20:29+00:00 https://beonemedaffairs.com/us/publication/sonrotoclax-overcomes-bcl2-g101v-mutation-induced-venetoclax-resistance-in-preclinical-models-of-hematologic-malignancy/ 2026-05-06T15:21:10+00:00 https://beonemedaffairs.com/us/publication/similar-efficacy-of-ibrutinib-arms-across-alpine-and-elevate-rr-trials-in-relapsed-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison/ 2026-05-06T15:21:53+00:00 https://beonemedaffairs.com/us/publication/disparity-in-treatment-patterns-among-medicare-beneficiaries-diagnosed-with-chronic-lymphocytic-leukemia-an-analysis-of-patient-and-contextual-factors/ 2026-05-06T15:32:39+00:00 https://beonemedaffairs.com/us/publication/cardiovascular-events-reported-in-patients-with-b-cell-malignancies-treated-with-zanubrutinib/ 2026-05-06T15:33:21+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and-etoposide-as-first-line-treatment-for-extensive-stage-sclc-rationale-312-a-multicenter-double-blind-placebo-controlled-r/ 2026-05-06T15:34:08+00:00 https://beonemedaffairs.com/us/publication/characterization-of-zanubrutinib-safety-and-tolerability-profile-and-comparison-with-ibrutinib-safety-profile-in-patients-with-b-cell-malignancies-post-hoc-analysis-of-a-large-clinical-trial-safety-d/ 2026-05-06T15:34:44+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-versus-sorafenib-in-first-line-treatment-of-unresectable-hepatocellular-carcinoma-impact-on-health-related-quality-of-life-in-rationale-301-study/ 2026-05-06T15:35:32+00:00 https://beonemedaffairs.com/us/publication/second-line-tislelizumab-versus-chemotherapy-in-japanese-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-subgroup-analysis-from-rationale-302/ 2026-05-06T15:36:12+00:00 https://beonemedaffairs.com/us/publication/tumor-immune-microenvironment-and-nrf2-associate-with-clinical-efficacy-of-pd-1-blockade-combined-with-chemotherapy-in-lung-squamous-cell-carcinoma/ 2026-05-06T15:36:50+00:00 https://beonemedaffairs.com/us/publication/saffron-103-a-phase-ib-study-of-sitravatinib-plus-tislelizumab-in-anti-pd-l1-refractory-resistant-advanced-melanoma/ 2026-05-06T15:37:29+00:00 https://beonemedaffairs.com/us/publication/biomarker-analysis-of-the-aspen-study-comparing-zanubrutinib-to-ibrutinib-in-patients-with-waldenstrom-macroglobulinemia/ 2026-05-06T15:38:08+00:00 https://beonemedaffairs.com/us/publication/genomic-landscape-of-patients-in-a-phase-ii-study-of-zanubrutinib-in-ibrutinib-and-or-acalabrutinib-intolerant-patients-with-b-cell-malignancies/ 2026-05-06T15:38:48+00:00 https://beonemedaffairs.com/us/publication/indirect-comparisons-of-efficacy-of-zanubrutinib-versus-orelabrutinib-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-or-relapsed-or-refractory-mantle-c/ 2026-05-06T15:39:35+00:00 https://beonemedaffairs.com/us/publication/bgb-a445-a-novel-non-ligand-blocking-agonistic-anti-ox40-antibody-exhibits-superior-immune-activation-and-antitumor-effects-in-preclinical-models/ 2026-05-06T15:40:15+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-european-and-north-american-patients-with-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-a-subgroup-analysis-of-the-randomized/ 2026-05-06T15:41:02+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-in-advanced-metastatic-esophageal-squamous-cell-carcinoma-health-related-quality-of-life-in-asian-patients/ 2026-05-06T15:41:43+00:00 https://beonemedaffairs.com/us/publication/advantig-105-a-phase-i-dose-escalation-study-of-the-anti-tigit-monoclonal-antibody-ociperlimab-in-combination-with-tislelizumab-in-patients-with-advanced-solid-tumors/ 2026-05-06T15:42:24+00:00 https://beonemedaffairs.com/us/publication/health-related-quality-of-life-outcomes-associated-with-zanubrutinib-versus-ibrutinib-monotherapy-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-resu/ 2026-05-06T15:43:04+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-vs-sorafenib-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma/ 2026-05-06T15:43:49+00:00 https://beonemedaffairs.com/us/publication/health-related-quality-of-life-in-treatment-naive-cll-sll-patients-treated-with-zanubrutinib-versus-bendamustine-plus-rituximab/ 2026-05-06T15:44:31+00:00 https://beonemedaffairs.com/us/publication/long-term-outcomes-of-second-line-versus-later-line-zanubrutinib-treatment-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-an-updated-pooled-analysis/ 2026-05-06T15:45:12+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-past-present-and-future/ 2026-05-06T15:45:52+00:00 https://beonemedaffairs.com/us/publication/safety-and-efficacy-of-zanubrutinib-in-relapsed-refractory-marginal-zone-lymphoma-final-analysis-of-the-magnolia-study/ 2026-05-06T15:46:34+00:00 https://beonemedaffairs.com/us/publication/the-effects-of-tislelizumab-treatment-on-the-health-related-quality-of-life-of-patients-with-advanced-non-small-cell-lung-cancer/ 2026-05-06T15:47:12+00:00 https://beonemedaffairs.com/us/publication/rosewood-a-phase-ii-randomized-study-of-zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma/ 2026-05-06T15:47:58+00:00 https://beonemedaffairs.com/us/publication/identification-and-characterization-of-an-unexpected-isomerization-motif-in-cdrh2-that-affects-antibody-activity/ 2026-05-06T15:48:38+00:00 https://beonemedaffairs.com/us/publication/discovery-of-bgb-8035-a-highly-selective-covalent-inhibitor-of-brutons-tyrosine-kinase-for-b-cell-malignancies-and-autoimmune-diseases/ 2026-05-06T15:49:33+00:00 https://beonemedaffairs.com/us/publication/targeted-protein-degrader-development-for-cancer-advances-challenges-and-opportunities/ 2026-05-06T15:50:14+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-versus-ibrutinib-in-symptomatic-waldenstrom-macroglobulinemia-final-analysis-from-the-randomized-phase-iii-aspen-study/ 2026-05-06T15:50:57+00:00 https://beonemedaffairs.com/us/publication/pamiparib-in-combination-with-tislelizumab-in-patients-with-advanced-solid-tumours-results-from-the-dose-expansion-stage-of-a-multicentre-open-label-phase-i-trial/ 2026-05-06T15:51:34+00:00 https://beonemedaffairs.com/us/publication/impact-of-atrial-fibrillation-in-onco-hematological-patients-in-europe-a-targeted-literature-review/ 2026-05-06T15:52:20+00:00 https://beonemedaffairs.com/us/publication/efficacy-and-safety-of-maintenance-therapy-with-pamiparib-versus-placebo-for-advanced-gastric-cancer-responding-to-first-line-platinum-based-chemotherapy-phase-2-study-results/ 2026-05-06T15:53:00+00:00 https://beonemedaffairs.com/us/publication/a-phase-1-open-label-fixed-sequence-drug-drug-interaction-study-of-zanubrutinib-with-rifabutin-in-healthy-volunteers/ 2026-05-06T15:53:37+00:00 https://beonemedaffairs.com/us/publication/treating-relapsed-refractory-mature-t-and-nk-cell-neoplasms-with-tislelizumab-a-multicenter-open-label-phase-2-study/ 2026-05-06T15:54:17+00:00 https://beonemedaffairs.com/us/publication/zanidatamab-for-her2-amplified-unresectable-locally-advanced-or-metastatic-biliary-tract-cancer-herizon-btc-01-a-multicentre-single-arm-phase-2b-study/ 2026-05-06T15:55:24+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer-a-multicenter-phase-3-trial-rationale-309/ 2026-05-06T15:56:05+00:00 https://beonemedaffairs.com/us/publication/co-enrichment-of-cd8-positive-t-cells-and-macrophages-is-associated-with-clinical-benefit-of-tislelizumab-in-solid-tumors/ 2026-05-06T15:56:41+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-rationale-306-a-global-randomised-placebo-co/ 2026-05-06T15:57:21+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-alone-and-in-combination-with-tislelizumab-for-the-treatment-of-richter-transformation-of-chronic-lymphocytic-leukemia-hemasphere/ 2026-05-06T15:58:02+00:00 https://beonemedaffairs.com/us/publication/molecular-associations-of-response-to-the-new-generation-btk-inhibitor-zanubrutinib-in-marginal-zone-lymphoma/ 2026-05-06T15:58:46+00:00 https://beonemedaffairs.com/us/publication/emerging-therapeutic-strategies-for-enhancing-sensitivity-and-countering-resistance-to-programmed-cell-death-protein-1-or-programmed-death%e2%80%90ligand-1-inhibitors-in-non-small-cell-lung-ca/ 2026-05-06T15:59:39+00:00 https://beonemedaffairs.com/us/publication/saffron-103-a-phase-1b-study-of-the-safety-and-efficacy-of-sitravatinib-combined-with-tislelizumab-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer/ 2026-05-06T16:00:20+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-final-results-and-correlative-analysis-of-lymphocytosis/ 2026-05-06T16:01:00+00:00 https://beonemedaffairs.com/us/publication/sars-cov-2-neutralising-antibody-bgb-dxp593-in-mild-to-moderate-covid-19-a-multicentre-randomised-double-blind-phase-2-trial/ 2026-05-06T16:02:08+00:00 https://beonemedaffairs.com/us/publication/a-phase-1-2-study-of-the-pd-l1-inhibitor-bgb-a333-alone-and-in-combination-with-the-pd-1-inhibitor-tislelizumab-in-patients-with-advanced-solid-tumours/ 2026-05-06T16:07:21+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-patients-with-relapsed-refractory-hairy-cell-leukemia/ 2026-05-06T16:09:11+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-patients-with-treatment-naive-or-relapsed-refractory-waldenstrom-macroglobulinemia-an-expanded-access-study-of-50-patients-in-the-united-states/ 2026-05-06T16:10:05+00:00 https://beonemedaffairs.com/us/publication/a-real-world-study-to-assess-the-association-of-cardiovascular-adverse-events-cvaes-with-ibrutinib-as-first-line-1l-treatment-for-patients-with-chronic-lymphocytic-leukaemia-cll-in-the-united-st/ 2026-05-06T16:10:55+00:00 https://beonemedaffairs.com/us/publication/managing-ibrutinib-intolerant-patients-with-b-cell-malignancies/ 2026-05-06T16:11:28+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-or-ibrutinib-in-relapsed-or-refractory-chronic-lymphocytic-leukemia/ 2026-05-06T16:12:07+00:00 https://beonemedaffairs.com/us/publication/a-phase-1-open-label-randomized-drug-drug-interaction-study-of-zanubrutinib-with-moderate-or-strong-cyp3a-inhibitors-in-patients-with-b-cell-malignancies/ 2026-05-06T16:12:53+00:00 https://beonemedaffairs.com/us/publication/pamiparib-in-patients-with-locally-advanced-or-metastatic-her2-negative-breast-cancer-with-germline-brca-mutations-a-phase-ii-study/ 2026-05-06T16:13:39+00:00 https://beonemedaffairs.com/us/publication/managing-waldenstroms-macroglobulinemia-with-btk-inhibitors/ 2026-05-06T16:16:48+00:00 https://beonemedaffairs.com/us/publication/unusual-complications-in-the-management-of-chronic-lymphocytic-leukemia/ 2026-05-06T16:17:30+00:00 https://beonemedaffairs.com/us/publication/approach-to-a-patient-with-double-refractory-chronic-lymphocytic-leukemia-double-double-toil-and-trouble-shakespeare/ 2026-05-06T16:18:09+00:00 https://beonemedaffairs.com/us/publication/management-of-relapsed-refractory-chronic-lymphocytic-leukemia/ 2026-05-06T16:18:58+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-monotherapy-for-naive-and-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-pooled-analysis-of-three-studies/ 2026-05-06T16:19:36+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-versus-ibrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-interim-analysis-of-a-randomized-phase-iii-trial/ 2026-05-06T16:20:13+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-patients-with-previously-treated-b-cell-malignancies-intolerant-of-previous-bruton-tyrosine-kinase-inhibitors-in-the-usa-a-phase-2-open-label-single-arm-study/ 2026-05-06T16:21:02+00:00 https://beonemedaffairs.com/us/publication/model-based-population-pharmacokinetic-analysis-of-tislelizumab-in-patients-with-advanced-tumors/ 2026-05-06T16:21:49+00:00 https://beonemedaffairs.com/us/publication/coming-of-age-for-btk-inhibitor-therapy-a-review-of-zanubrutinib-in-waldenstrom-macroglobulinemia/ 2026-05-06T16:22:31+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-in-patients-with-previously-treated-advanced-hepatocellular-carcinoma-rationale-208-a-multicenter-non-randomized-open-label-phase-2-trial/ 2026-05-06T16:23:17+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-versus-docetaxel-in-patients-with-previously-treated-advanced-nsclc-rationale-303-a-phase-3-open-label-randomized-controlled-trial/ 2026-05-06T16:24:04+00:00 https://beonemedaffairs.com/us/publication/management-of-front-line-chronic-lymphocytic-leukemia/ 2026-05-06T16:24:56+00:00 https://beonemedaffairs.com/us/publication/a-phase-ii-study-of-zanubrutinib-in-combination-with-rituximab-in-patients-with-relapsed-refractory-aggressive-and-indolent-b-cell-lymphoma/ 2026-05-06T16:25:40+00:00 https://beonemedaffairs.com/us/publication/real-world-longitudinal-practice-patterns-in-the-use-of-pd-1-and-pd-l1-inhibitors-as-first-line-therapy-in-patients-with-non-small-cell-lung-cancer-in-the-united-states/ 2026-05-06T16:26:30+00:00 https://beonemedaffairs.com/us/publication/a-clinical-practice-comparison-of-patients-with-chronic-lymphocytic-leukemia-with-and-without-deletion-17p-receiving-first-line-treatment-with-ibrutinib/ 2026-05-06T16:27:05+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-versus-bendamustine-and-rituximab-in-untreated-chronic-lymphocytic-leukaemia-and-small-lymphocytic-lymphoma-sequoia-a-randomised-controlled-phase-3-trial/ 2026-05-06T16:27:54+00:00 https://beonemedaffairs.com/us/publication/the-combination-of-gene-hyperamplification-and-pd-l1-expression-as-a-biomarker-for-the-clinical-benefit-of-tislelizumab-in-gastric-gastroesophageal-junction-adenocarcinoma/ 2026-05-06T16:28:45+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-versus-chemotherapy-as-second-line-treatment-of-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-rationale-302-impact-on-health-related-quality-of-life/ 2026-05-06T16:29:25+00:00 https://beonemedaffairs.com/us/publication/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-rationale-302-a-randomized-phase-iii-study/ 2026-05-06T16:30:04+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-lymphoproliferative-disorders-a-comprehensive-review/ 2026-05-06T16:30:45+00:00 https://beonemedaffairs.com/us/publication/small-cell-lung-cancer-patients-treated-with-immune-checkpoint-inhibitor-a-systematic-literature-review-of-treatment-efficacy-safety-and-quality-of-life/ 2026-05-06T16:31:27+00:00 https://beonemedaffairs.com/us/publication/btk-inhibitors-and-car-t-cell-therapy-in-treating-mantle-cell-lymphoma-finding-a-dancing-partner/ 2026-05-06T16:32:11+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-monotherapy-in-relapsed-refractory-indolent-non-hodgkin-lymphoma/ 2026-05-06T16:32:53+00:00 https://beonemedaffairs.com/us/publication/a-two-part-single-arm-multicentre-phase-i-study-of-zanubrutinib-a-selective-bruton-tyrosine-kinase-inhibitor-in-chinese-patients-with-relapsed-refractory-b-cell-malignancies/ 2026-05-06T16:33:40+00:00 https://beonemedaffairs.com/us/publication/examining-the-impact-of-tislelizumab-added-to-chemotherapy-on-health-related-quality-of-life-outcomes-in-previously-untreated-patients-with-nonsquamous-non-small-cell-lung-cancer/ 2026-05-06T16:34:18+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-for-the-treatment-of-b-cell-malignancies/ 2026-05-06T16:34:54+00:00 https://beonemedaffairs.com/us/publication/zanubrutinib-in-relapsed-refractory-mantle-cell-lymphoma-long-term-efficacy-and-safety-results-from-a-phase-2-study/ 2026-05-06T16:35:35+00:00 https://beonemedaffairs.com/us/publication/a-rapid-2ab-uhplc-method-based-on-magnetic-beads-extraction-for-n-glycan-analysis-of-recombinant-monoclonal-antibody/ 2026-05-06T16:36:13+00:00 https://beonemedaffairs.com/us/publication/phase-1b-2-study-of-zanidatamab-in-combination-with-tislelizumab-and-chemotherapy-in-first-line-her2-positive-gastric-gastroesophageal-junction-adenocarcinoma/ 2026-05-06T17:27:16+00:00 https://beonemedaffairs.com/us/publication/first-line-treatment-for-cll-in-the-era-of-targeted-therapy/ 2026-05-09T11:28:47+00:00 https://beonemedaffairs.com/us/publication/comparative-efficacy-of-zanubrutinib-plus-obinutuzumab-versus-last-prior-treatment-in-relapsed-refractory-follicular-lymphoma-growth-modulation-index-analysis-from-the-rosewood-study/ 2026-05-09T11:48:40+00:00 https://beonemedaffairs.com/us/publication/an-fc-competent-anti-human-tigit-blocking-antibody-ociperlimab-bgb-a1217-elicits-strong-immune-responses-and-potent-anti-tumor-efficacy-in-pre-clinical-models/ 2026-05-19T13:26:08+00:00